ZeNix
2022
Bedaquiline-Pretomanid-Linezolid Regimens for MDR/XDR-TB
In 181 patients with MDR or XDR tuberculosis, BPaL with linezolid 600 mg for 26 weeks preserved favourable outcome while reducing toxicity compared with linezolid 1200 mg for 26 weeks.
Result
Primary endpoint: Favourable outcome at 6 months post-treatment
Favourable outcome ~91% in linezolid-600/26-wk arm; overall risk-benefit favoured this arm (less peripheral neuropathy/myelosuppression, fewer dose modifications).
- Subtopic
- MDR/XDR-TB
- Design
- Phase 3 dose-finding RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Conradie F, et al. N Engl J Med. 2022;387(9):810-823.doi 10.1056/NEJMoa2119430
Discussion & critique
Defined the optimal linezolid dose for BPaL: preserves efficacy and protects the peripheral nervous system.